

Press Release:

For Immediate Distribution

**Panacea Biotec Ensures limited availability of Life Saving Drug  
Cilamin 250 Capsule (D- Penicillamine IP 250 mg)**

**New Delhi, 28th September, 2016:**

**Cilamin 250 Capsule** used for treatment of Wilsons disease, Rheumatoid Arthritis and other conditions witnessed short supply in the market during the last few months due to non-availability of raw material D-Penicillamine in India.

**Panacea Biotec, India's leading biotechnology company hereby informs all Doctors, Patients and Families, Stockiest and Chemists that our brand Cilamin 250 Capsules for treatment of above conditions has been made available in limited quantities in the retail market.**

The temporary shortage is due to sudden disruption of supplies of raw material by qualified supplier beyond the control of the company. Since then company has been working tirelessly with alternate suppliers for supply of this raw material.

**Due to continuous efforts we have resumed limited production of Cilamin 250 and have released limited quantities in the market from 26.9.2016.**

**Some of the key initiatives taken by Panacea Biotec to ensure availability of Cilamin 250 to patients are as follows:-**

1. Delivered **Cilamin 250** to approximately **300** patients so far by rationing safety stocks to all who could reach us through various forums.
2. Launched a website [www.cilamin.com](http://www.cilamin.com) for emergency supplies to patients and for access to latest information on its availability.
3. Formed a **WhatsApp Group Cilamin Support (+91 9350588528)** of Patients, Doctors, Company Executives for monitoring and support.
4. Formed Twitter handler **@Cilamin250** for real time communication
5. Formed Facebook page <https://www.facebook.com/cilamin250> for real time communication.



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: [corporate@panaceabiotec.com](mailto:corporate@panaceabiotec.com)

CIN: L33117PB1984PLC022350

6. **Supply of new batches with limited quantities of Cilamin 250 have started from 26.9.16 from our manufacturing facility at Baddi under Good Manufacturing Practices.**

We continue to work closely with existing and potential new raw material suppliers in China and India for access to the raw material in an accelerated manner.

We are in touch with Drug Controller General of India office for allowing imports of raw material in parallel to registration process under this emergency situation to ensure continuous access of this medicine to patients while other alternative sources in India are being also worked upon in an aggressive manner.

**As per current estimates we expect it would take additional 2-4 weeks for access to additional quantities of raw material and additional 4 weeks for Cilamin 250 supplies to normalize.**

Panacea Biotec is committed to do what all it takes to ensure continuous and sustainable access of good quality Cilamin 250 a critical lifesaving drug to patients and will keep posting latest development on its availability at our website [www.cilamin.com](http://www.cilamin.com).

**We apologize for the inconvenience caused to Patients, Families, Doctors and all other stakeholders due to this shortage.**

### Notes to the Editors

#### About Panacea Biotec

Panacea Biotec is one of India's leading research based Biotechnology Company with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 3 biotechnology companies (Biospectrum – ABLE Survey, July 2014) and the top 50 pharmaceutical companies (AIOCD AWACS – MAT May 2016) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of Oncology, Organ Transplantation, Nephrology, Diabetes, Osteoporosis, and Pediatric Immunization Vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro particles, liposomes, gastro-retentive systems. Panacea Biotec has introduced its products in 22 countries across the world including USA and Germany through a combination of strategic





*Innovation in support of life*

collaborations and direct presence in select geographies. Panacea Biotec has research collaborations with leading national and international research organizations and corporations. Panacea Biotec's state of the art manufacturing facilities for Vaccines and Pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2700 employees including around 125 scientists working across 4 R&D centers of the company.

**For more information, please contact –**

**Mr. P. D. Karan**

**Vice President - Corporate Communication & Business Development**

**B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,  
Mathura Road, New Delhi – 110044, INDIA**

**Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)**

**Fax + 91 11 41578002**

**Mobile: + 91 9312693040**

**Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com)**

**Web: [www.panaceabiotec.com](http://www.panaceabiotec.com)**

B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi – 110 044, India  
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: [corporate@panaceabiotec.com](mailto:corporate@panaceabiotec.com)  
CIN: L33117PB1984PLC022350